Frespaciguat

Merck's frespaciguat (MK-5475) is an inhaled soluble guanylate cyclase (sGC) stimulator in Phase 2 for pulmonary hypertension caused by COPD (PH-COPD), an indication where every prior oral sGC stimulator has failed for a specific reason: systemic vasodilation makes sick lungs worse by disrupting how blood flow matches airflow. The inhaled route is the whole thesis. Deliver the drug directly to the pulmonary vasculature, keep sGC activation local, avoid the mortality signal that terminated riociguat's RISE-IIP trial in PH-ILD in 2016 [1]. INSIGNIA-PH-COPD (NCT05612035, n=129) is active-not-recruiting with 6-minute walk distance at week 24 as the primary endpoint [2]. A parallel Phase 2/3 in classical pulmonary arterial hypertension (NCT04732221, n=168) has completed enrollment [3]. The closest regulatory precedent is inhaled treprostinil (Tyvaso), approved for PH-ILD in 2021 based on the INCREASE trial showing a +31m placebo-adjusted 6MWD improvement [14][15]. If the safety and efficacy story holds, Merck opens a graveyard indication where a large fraction of severe COPD patients develop clinically meaningful pulmonary hypertension with zero approved targeted therapies for the PH-COPD subset specifically.

Novel compound, no approvals anywhere. Merck development code MK-5475. Lead indication is PH-COPD in INSIGNIA-PH-COPD (NCT05612035), Phase 2 with 129 participants, active but not recruiting, meaning enrollment closed and readout is pending [2]. Primary endpoint is mean change from baseline in 6-minute walk distance (6MWD) at week 24, a standard functional measure in pulmonary hypertension trials. Merck is also running INSIGNIA-PAH (NCT04732221), a Phase 2/3 trial in classical pulmonary arterial hypertension with n=168 that has completed enrollment [3]. Two Phase 1 studies established pharmacology. NCT03744637 (MK-5475-002) was a single-dose Phase 1 study in Group 1 PAH patients (n=8 in the dose-escalation part), measuring pulmonary vascular resistance via right heart catheterization; all tested doses reduced PVR by roughly 20% or more without systemic blood pressure effects [4]. NCT04370873 (MK-5475-006) was a Phase 1 in PH-COPD patients with n=22, completed [5]. A published Phase 1 drug-drug interaction study showed frespaciguat co-administered with sildenafil (a PDE5 inhibitor already used in PAH) did not cause problematic additive hypotension [6], which matters commercially because most PAH patients are already on PDE5 inhibitors and combination compatibility is required. A radiolabeled mass balance study characterized metabolism and elimination [7]. No FDA breakthrough therapy, fast track, or orphan designations have been publicly disclosed. Readout timing for INSIGNIA-PH-COPD has not been formally guided, but active-not-recruiting status suggests data within roughly 12 to 18 months (expected 2026 to 2027).

Soluble guanylate cyclase (sGC) is the enzyme inside vascular cells that produces cyclic GMP (cGMP), a second messenger that tells smooth muscle to relax. Nitric oxide (NO), released by healthy blood vessel lining, is the natural activator. In pulmonary hypertension, NO signaling is broken: the endothelium is damaged and NO production is low. sGC stimulators like frespaciguat and riociguat sensitize heme-intact sGC to low levels of NO and boost basal cGMP production independently of NO. They require the enzyme's heme moiety to be intact (ferrous Fe2+); they do not effectively activate oxidized or heme-free sGC. Rescuing oxidized sGC is the role of a separate drug class, sGC activators (cinaciguat class). In PH, the therapeutic benefit of a stimulator is compensating for depleted NO availability, not rescuing irreversibly oxidized enzyme. Two sGC stimulators are already approved. Riociguat (Adempas, Bayer) got FDA approval in 2013 for pulmonary arterial hypertension based on the PATENT-1 trial [8] and for chronic thromboembolic pulmonary hypertension based on the CHEST-1 trial [13], both showing meaningful 6MWD gains vs. placebo [9]. Vericiguat (Verquvo, Merck/Bayer) was approved in 2021 for heart failure with reduced ejection fraction after the VICTORIA trial [10]. The mechanism is validated in pulmonary vasculature. What is not validated is safe use in patients with parenchymal lung disease. Riociguat's RISE-IIP trial in PH associated with interstitial lung disease was stopped early in 2016 for increased mortality: systemic vasodilation worsened ventilation-perfusion (V/Q) matching by dilating vessels serving poorly-ventilated lung regions, dropping oxygen [1]. That failure produced a hard label warning against oral sGC stimulators in PH due to lung disease. Inhaling frespaciguat is designed to concentrate the drug where it matters and stay below the systemic exposure that would recreate the V/Q problem. Whether that carveout satisfies regulators, given the class label warning applies to riociguat's oral formulation, is a live question Merck will need to address at NDA.

INSIGNIA-PH-COPD (NCT05612035) is a Phase 2 trial in adults with pulmonary hypertension caused by COPD, enrolling 129 participants, currently active-not-recruiting [2]. The primary endpoint is mean change from baseline in 6MWD at week 24. 6MWD is the workhorse endpoint in PH trials because it correlates with functional status and has supported multiple approvals, though it is noisy and can be affected by comorbidities. A 30-meter change is generally considered clinically meaningful. PATENT-1 for riociguat in PAH showed a placebo-adjusted 36-meter improvement [8]. The most relevant recent precedent is inhaled treprostinil in PH-ILD: the INCREASE trial (Waxman et al. NEJM 2021) showed a +31m placebo-adjusted 6MWD gain, which supported FDA approval of Tyvaso for PH-ILD in 2021 [14][15]. INCREASE studied PH-ILD, not PH-COPD, so it is not a direct comparator, but it establishes that inhaled delivery is an acceptable regulatory route for Group 3 PH and sets the ballpark efficacy bar payers and regulators will apply. In COPD-associated PH, most patients are older, more debilitated, and often exercise-limited by their airway disease as much as by pulmonary vascular resistance. That confounder is real, and any improvement has to be attributable to reducing pulmonary vascular resistance rather than placebo effect or trial-related conditioning. Design details around stratification by PH severity and secondary endpoints (hemodynamics, NT-proBNP, quality of life) will determine how interpretable the readout is. Comparator arm is not spelled out in the public registry summary, though Phase 2 PH trials of this design are almost always placebo-controlled. INSIGNIA-PAH (NCT04732221) is the parallel Phase 2/3 program in classical PAH with n=168 and completed enrollment [3]. Readout from either study could re-price the other.

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 27%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results, heavier-than-usual blinding, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest single failure mode. 6MWD in PH-COPD is hard to move because patients are exercise-limited by airway obstruction, not just pulmonary vascular resistance. The trial has to demonstrate that reducing PVR translates to a walk-distance benefit above and beyond COPD-driven baseline decline. Placebo effects in 6MWD trials are notoriously large. A delta under 25 meters may reach statistical significance without clearing the bar payers or regulators want, and the INCREASE benchmark of +31m for inhaled treprostinil in PH-ILD [14] is a reasonable floor for a competitive read. Safety risk is mechanism-based and specific. Systemic sGC stimulators worsen V/Q matching in patients with heterogeneous lung disease by dilating vessels perfusing poorly-ventilated regions, which drops oxygen. This is why the RISE-IIP trial of riociguat in PH-ILD was stopped in 2016 for excess mortality [1]. Inhaled delivery is designed to keep systemic exposure low enough to avoid recreating this, but the boundary between local pulmonary effect and systemic spillover is not clean. Any hypoxemia or exercise oxygen desaturation signal in INSIGNIA-PH-COPD would be a red flag reviewers scrutinize hard. Regulatory risk includes the class label warning against sGC stimulators in PH due to lung disease, which was written for oral riociguat. Merck must convince FDA that the inhaled route creates a genuine PK carveout rather than a marketing rebrand of the same mechanism. This is a live question at NDA, not a solved problem. Execution risk is low. Merck runs pulmonary programs competently and enrollment is already closed. Commercial risk hinges on payer positioning. Even if approved, PH-COPD is not routinely screened for and cardiology-to-pulmonology referral pathways for this population are underdeveloped. Payers will want evidence that treatment changes hospitalization or mortality, not just walk distance. An inhaled device adds cost, adherence friction, and manufacturing complexity that oral sGC stimulators like vericiguat do not carry. IP/patent horizon has not been publicly disclosed by Merck for MK-5475 specifically; composition-of-matter protection for a compound entering Phase 2 in 2025 typically extends into the mid-2030s before generic entry, with device patents adding some additional runway.

Worth watching, mostly because a positive PH-COPD signal would be genuinely category-creating. There are no approved drugs for PH-COPD specifically and standard of care is treat the COPD, hope the PH resolves, transplant if it does not. Roughly 20 to 30% of patients with severe COPD develop clinically meaningful pulmonary hypertension, translating to a US patient pool on the order of 400,000-plus with severe COPD and a substantial subset with concurrent PH. A smaller fraction have severe PH out of proportion to their airway disease, which is the highest-priority target population. That is a real unmet need with clean commercial logic. The signal to watch in INSIGNIA-PH-COPD is two numbers: placebo-adjusted 6MWD change and any oxygen desaturation or SAE imbalance. A delta above 30 meters with a clean safety profile would be a genuine breakthrough for this class and would sit at or above the INCREASE benchmark [14]. A delta under 20 meters or any hypoxemia trend would confirm the class problem and likely kill the program. INSIGNIA-PAH data will land first and function as a sanity check on the molecule and its inhaled delivery system [3], though the PAH commercial thesis is harder than PH-COPD: the PAH market has 8-plus approved therapies across five classes with generic sildenafil and tadalafil dominating first-line, and inhaled treprostinil (Tyvaso, plus the Tyvaso DPI dry-powder formulation) is the only other inhaled option. Merck must justify premium pricing on the inhaled device versus cheap oral generics, which is a real ask absent standout efficacy or safety differentiation. Merck ($64.2B in 2024 revenue per its 2024 10-K [12]) can absorb a PH-COPD failure without material impact; the commercial thesis rests on incremental respiratory portfolio value rather than blockbuster expectations. Check back after any INSIGNIA-PAH data and again after INSIGNIA-PH-COPD readout, expected 2026 to 2027 based on active-not-recruiting status.